ViralClear-Publishes-Comparative-In-Vitro-Data-on-Merimepodib-and-Remdesivir-Activity-Against-the-COVID-19-Novel-Coronavirus-in-F1000-Research.htm

Les cookies nous permettent de vous proposer nos services plus facilement. En utilisant nos services, vous nous donnez expressément votre accord pour exploiter ces cookies.En savoir plus OK

Le pdf se trouve ci-dessous. Vous pouvez télécharger le pdf en cliquant à droite.

Revenir à l'accueil

Au format texte :

GlobeNewswire Intrado Logo Search REGISTER SIGN IN ENGLISH FRANÇAIS CONTACT US GLOBAL DISTRIBUTION NEWSWIRE SERVICES REGULATORY FILINGS MEDIA PARTNERS Bio-Sig-Logo-horiz.jpg ViralClear Publishes Comparative In Vitro Data on Merimepodib and Remdesivir Activity Against the COVID-19 Novel Coronavirus in F1000 Research Email Print Friendly Share April 23, 2020 09:15 ET | Source: BioSig Technologies, Inc. Westport, CT, April 23, 2020 (GLOBE NEWSWIRE) -- Merimepodib is shown to decrease viral production of COVID-19 coronavirus more than remdesivir at clinically meaningful drug concentrations in pre-clinical testing. Article highlights recent work done in laboratory studies of COVID-19 with merimepodib at the Galveston National Laboratory at The University of Texas Medical Branch BioSig Technologies, Inc. (Nasdaq: BSGM) today announced that an article titled, “The IMPDH inhibitor merimepodib has similar antiviral activity against SARS-CoV-2 replication in vitro to the adenosine analogue remdesivir” was accepted by F1000 Research, an online peer-reviewed life sciences journal publishing program in biology and medicine. This manuscript is authored by Natalya Bukreyeva, Rachel A. Sattler, Emily K. Mantlo, John T. Manning, Cheng Huang and Slobodan Paessler of the UTMB Galveston National Laboratory and Dr. Jerome Zeldis of ViralClear Pharmaceuticals, Inc. (“ViralClear”) as a corresponding author. The article highlights emerging pre-clinical data generated under contract with Galveston National Laboratory at The University of Texas Medical Branch. The work was started with Trek Therapeutics and after merimepodib was acquired by ViralClear has been continued by ViralClear. “The concentrations of merimepodib used in the cell culture studies described in this article are achievable in humans by our oral solution formulation,” said Dr. Zeldis, Executive Chair and Founder of ViralClear Pharmaceuticals, Inc. “We are now exploring whether remdesivir and merimepodib are synergistic in this in vitro model. We look forward to starting our first clinical trial in COVID-19 patients upon receiving FDA clearance to commence with the proposed phase 2 trial.” Vero cells in tissue culture were pre-treated with two concentrations (2.5 and 5 µM) of either merimepodib or remdesivir for 4 hours before the SARS-CoV-2 coronavirus was added. The amount of virus released to the media was measured at baseline and 16 hours and 24 hours after infection. At 16 hours, a significant reduction in viral production was observed for both concentrations of merimepodib (1.9 log decrease in titer, p = 0.003 and 2.1 log decrease in titer, p = 0.001) but only at the higher concentration of remdesivir (1 log decrease in titer, p = 0.103 and 2.1-log decrease in titer, p = 0.001). At 24 hours both concentrations of both drugs significantly reduced viral production; however, 2.5 µM remdesivir reduced viral titer by 1.5 logs (p = 0.002) as compared to a decrease of 3.9 logs for 5 µM remdesivir (p < 0.001), whereas 2.5 and 2.7 log reductions (p = 0.001 and p < 0.001, respectively) were observed for the 2.5 and 5 µM concentrations of merimepodib. Merimepodib, a broad-spectrum anti-viral candidate, demonstrated strong activity against COVID-19 in cell cultures in laboratory testing and additional antiviral studies are underway. Merimepodib was previously in development as a treatment for chronic hepatitis C and psoriasis by Vertex Pharmaceuticals Incorporated (Vertex), with a 12 clinical trials conducted (including 315 chronic hepatitis C patients, 24 psoriasis patients, and 98 healthy volunteers) and an extensive preclinical safety package completed . ViralClear intends to pursue development of this agent for the treatment of COVID-19 through FDA-approved clinical trials in Q2 2020. About BioSig Technologies BioSig Technologies is a medical technology company commercializing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals (www.biosig.com). The Company’s first product, PURE EP(tm) System is a computerized system intended for acquiring, digitizing, amplifying, filtering, measuring and calculating, displaying, recording and storing of electrocardiographic and intracardiac signals for patients undergoing electrophysiology (EP) procedures in an EP laboratory. About ViralClear BioSig’s subsidiary ViralClear Pharmaceuticals, Inc., is seeking to develop a novel pharmaceutical to treat advanced COVID-19. Merimepodib is a broad-spectrum anti-viral agent that has demonstrated strong activity against the COVID-19 virus in cell cultures in laboratory testing. ViralClear plans to initiate a multi-center, phase 2, randomized, double-blind, placebo-controlled study of the efficacy and safety of merimepodib administered orally every eight hours for 10 days in adult patients with advanced COVID-19 upon FDA clearance to proceed. Merimepodib has been studied in twelve clinical trials prior to this study, including five trials in patients with hepatitis C (one phase 1b, one phase 2, two phase 2a, and one phase 2b), one trial in patients with psoriasis (phase 2), and six trials in healthy volunteers (all phase 1). Forward-looking Statements This press release contains “forward-looking statements.” Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward- looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) the geographic, social and economic impact of COVID-19 on our ability to conduct our business and raise capital in the future when needed, (ii) our inability to manufacture our products and product candidates on a commercial scale on our own, or in collaboration with third parties; (iii) difficulties in obtaining financing on commercially reasonable terms; (iv) changes in the size and nature of our competition; (v) loss of one or more key executives or scientists; and (vi) difficulties in securing regulatory approval to market our products and product candidates. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC’s website at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise. Andrew Ballou BioSig Technologies, Inc. Vice President, Investor Relations 54 Wilton Road, 2nd floor Westport, CT 06880 aballou@biosigtech.com 203-409-5444, x133 Related Articles More articles issued by BioSig Technologies, Inc. More articles related to: Company Announcement Profile BioSig Technologies, Inc. Subscribe via RSS Subscribe via ATOM Javascript Westport, Connecticut, UNITED STATES Contact Data Andrew Ballou BioSig Technologies, Inc. Vice President, Investor Relations 54 Wilton Road, 2nd floor Westport, CT 06880 aballou@biosigtech.com 203-409-5444, x133 Contact Biosig Technologies (BSGM) Intraday 3 Month 6 Month 1 Year Last: $7.50 Change: +0.30 % Change: +4.17% Volume: 1M Open: $7.14 Previous Close: $7.20 Low: $7.14 High: $8.32 Market Cap: 0 Shares Outs.: 0 EPS: 0.00 P/E Ratio: - Dividend: N/A Yield: N/A 52 Week Low: $2.36 52 Week High: $9.97 Quote delayed at least 20 mins. Media Files Bio-Sig-Logo-horiz.jpg Logo Download Options Bio-Sig-Logo-horiz.jpg LOGO URL | Copy the link below http://www.globenewswire.com/attachment-download-view/2021020/564767/4/1/0/564767.jpg Tags HEALTHMEDICALelectrophysiologystocknasdaqdeviceinvestorarrhythmiaAfibVTheartEPscienceablationbioelectronic medicine Related Links https://www.biosig.com/ Newswire Distribution Network & Management Home Newsroom RSS Feeds Legal About Us GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public. © 2020 GlobeNewswire, Inc. All Rights Reserved. Trinidad and Tobago Newsday News Latest Sports Sections N Touch NEWS Hypertension patients, diabetics at high risk for covid 19 RYAN HAMILTON-DAVIS 4 HRS AGO File photo - File photo - The elderly are not the only people especially at risk for contracting covid19. People with hypertension, diabetes and kidney disease are also at high risk. So said Dr Neil Bhagwandass, nephrologist at San Fernando Hospital, at the Wednesday's covid19 update at the Ministry of Health headquarters on Park Street in Port of Spain. He listed the categories of people especially susceptible to the disease, which also included people who have suffered strokes or who have had lung diseases. Trendingview all 1 Designer defends $75, $100 cloth masks after backlash NARISSA FRASER 2 SORT foils alleged murder plot SHANE SUPERVILLE 3 Two held in Barrackpore after chase, 2 on the run LAUREL V WILLIAMS 4 Deyalsingh: Suspected case at step-down facility SHANE SUPERVILLE 5 Judge orders couple’s release JADA LOUTOO 6 ‘Stay at home’ challenged JADA LOUTOO 7 Brother, sister gunned down at home LAUREL V WILLIAMS Comments "Hypertension patients, diabetics at high risk for covid 19" More in this section NEWS Msgr Pereira: Spread Muslim fast to other religions YVONNE WEBB NEWS Corporations get $1m each to fight covid19 YVONNE WEBB NEWS CoP calls on public: Give info to reduce murders SHANE SUPERVILLE NEWS Attorney: People may sue over roadblocks SEAN DOUGLAS Trinidad and Tobago Newsday© 2020 Trinidad and Tobago Newsday. N Touch About Us Staff Classifieds Advertise Privacy Policy Contact Us Share to Facebook Share to WhatsApp Share to Twitter Share to Email Share to Print More AddThis Share options Skip to main content Thursday 23 April, 2020 Loop Market Trinidad And Tobago Home Search T&T News World News COVID-19 Carnival Viral Entertainment Lifestyle Business Sport BREAKING NEWS | Over 300,000 with hypertension at higher COVID-19 risk, says Minister ALINA DOODNATH CREATED : 23 APRIL 2020COVID-19[iStock.com/FatCamera] [iStock.com/FatCamera] Thousands of Trinidadians with diabetes and hypertension are at a higher risk due to the novel coronavirus (COVID-19), which if it spreads, ‘could be a disaster’, according to the Health Ministry. Speaking at Thursday’s media briefing to update the public on COVID-19 measures, Health Minister Terrence Deyalsingh said 341,000 people were diagnosed with hypertension, according to Ministry statistics – 23.6 percent of the population. He added that 266,000 (20.5 percent) of the population suffer from diabetes, saying that the figure is probably an underestimation as many people may not be aware they have diabetes. Dr Neal Bhagwandass, Nephrologist and Acting Head of Department, Medicine, at the San Fernando General Hospital, said it is critical that dialysis patients do not contract or spread the virus when receiving treatment. He said there are approximately 1,400 patients receiving hemodialysis treatments through the public health care system. "A typical dialysis would have 20-30 patients dialysing at one time. Our nephrologists have instituted policies so that patients are not allowed to congregate. Patients should be kept at least six feet apart and as soon as the dialysis procedure is finished they are to leave the environment." He said dialysis patients are screened on entering and are asked about any flu-like systems. "If we have to swab, swab them because this is a very high-risk population...we do not want COVID-19 to spread among our dialysis population, that could be a disaster." Dr Bhagwandass said those patients can experience kidney failure if they were to contract the virus. Dr Bhagwandass said diabetic patients should not work if they are feeling unwell. “Any stress on a diabetic patient would predispose you to your diabetes going out of control. These people should practice ‘sick day’ guidelines. If you become unwell, you develop…flu-like symptoms, your blood sugar would spike. “The rule is not to stop your diabetic medicine…get in contact with your health professionals for further advice.” Also concerning is the fact that young people who tested positive for the virus in other countries have been seen to develop abnormal clotting due to the virus. “Even young people who do not manifest these (diseases), are being diagnosed with strokes, cardiovascular accidents, because of increased clotting that occurs when one develops a COVID-19 infection.” People with the following conditions are at higher risk of severe COVID-19 complications: - Asthmatics - Chronic lung disease - Diabetes - Serious heart conditions - Chronic kidney disease/Dialysis - Severe obesity - Elderly (65 years and older) - Carehome residents - Immunocompromised - Liver disease Deyalsingh said the Ministry has implemented several measures to reduce the prevalence of non-communicable diseases including the banning of soft drinks at public schools, which he said has reduced soft drink consumption among children by 25 percent. He added that over the past year there was a drop in visits to the Accident and Emergency departments by 1.5 to two percent for people with hypertension and diabetes. Get the latest local and international news straight to your mobile phone for free: DIALYSIS DIABETES HYPERTENSION MINISTRY HEALTH DR ROSHAN PARASRAM DR NEAL BHAGWANDASS TRINIDAD CORONAVIRUS COVID-19 Related articles Comments Share this article Share to FacebookShare to TwitterShare to LinkedInShare to WhatsAppShare to MessengerShare to EmailShare to TelegramShare to More124 Trending Recent News Loop News Theme SECTIONS T&T NewsWorld NewsCOVID-19CarnivalViralEntertainmentLifestyleBusinessSport LOOP NEWS Privacy PolicyComments PolicyAbout UsContact UsSubmit an Article NEWSLETTER Email COPYRIGHT 2017 BY TREND MEDIA | ALL RIGHTS RESERVED Electropages icon Electropages uses cookies to give you the best experience. I'm fine with thisInformation and Settings Electropages logo Home Insights Product News NPI Channels Search Term Magnifying glass icon Tetherless pulse oximeter can monitor COVID-19 patients at home 23-04-2020 | Nordic | Test & Measurement Nordic Semiconductor is meeting demand for its high-end Bluetooth SoC. This lies at the heart of an industry-leading, battery-powered wireless pulse oximeter, the Radius PPG, that was launched last year by Masimo and is now set to join the front-line battle against COVID-19 as part of that company's SafetyNet solution. As the Radius PPG is created to enable tetherless monitoring, it can be used as part of the SafetyNet platform to remotely manage COVID-19 patients at home and conceivably assist hospitals from being overwhelmed by less severe cases. "We didn't originally develop Radius PPG to combat COVID-19," says Bilal Muhsin, chief operating officer, Masimo. "We first and foremost developed it so it could monitor hospital patients accurately, even when the patient is moving, without the inconvenience of a wired connection to a monitor. But it turns out that in the current COVID-19 crisis this tetherless capability, when paired with a secure, cloud-based telehealth platform accessible from a smartphone for patients and from a web-based dashboard for providers, can provide a valuable way to manage COVID-19 patients who do not require hospitalisation. And continue to check them from their homes, allowing hospital beds to be freed up for those who need it. Masimo SafetyNet uses the same Radius PPG tetherless pulse oximeter designed for use in the hospital to provide a remote patient management solution small enough to be worn comfortably and simple enough to be set-up quickly on the patient's smartphone." "Our hearts go out to the brave front line medical and hospital personnel doing their absolute best to cope with the often overwhelming numbers of COVID-19 patients coming through their doors in COVID-19 hotspots around the world," concludes Geir Langeland, Nordic Semiconductor director of sales and marketing. Nordic's latest multiprotocol SoC is its most advanced ultra low power wireless solution. The SoC supports complex Bluetooth LE and other wireless applications that were previously not possible with a single-chip solution. Nordic logo Facebook icon Twitter icon LinkedIn icon Email icon Print icon Related product news Next generation proximity sensors for GAPS and HAPS 22-04-2020 | Test & Measurement Motion detector aids designers in adding different technologies 21-04-2020 | Test & Measurement New sensor solution for ventilators 20-04-2020 | Test & Measurement Cost-effective MEMS sensors give increased performance and reliability 17-04-2020 | Test & Measurement Information Contact Us About Archive Submit PR Advertise Manage newsletter Subscribe Manage Subscription RSS feeds Our apps Apple icon Android icon Social profiles Facebook icon Twitter icon All news & general enquiries: +44 (0)1202 237137 info@electropages.com Copyright © 2020 Electropages Media Ltd Cookie Policy | Privacy Policy Electropages Media logo